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Background: Headache chronicity has been known to elicit deleterious effects on quality of life (QOL). We
evaluated the contribution of headache chronicity to QOL in relation to clinical, psychiatric, and psychosocial
variables in patients with migraine.
Methods: Subjects were recruited from a headache clinic and completed self-report questionnaires including the
Migraine Disability Assessment (MIDAS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and
Migraine-Specific Quality of Life (MSQoL). We obtained predictors of MSQoL by multiple regression analyses. A path
analysis model was constructed to analyze interrelationships between the variables.
Results: Among 251 eligible patients, 183 (72.9%) had episodic migraine (EM) and 68 (27.1%) had chronic migraine
(CM). Patients with CM had more serious clinical, psychiatric, and poor QOL than did patients with EM. The
strongest predictor of the MSQoL score in all patients with migraine was the BDI score (β = -0.373, p < 0.001),
followed by the MIDAS score (β = -0.223, p < 0.001), female gender (β = -0.192, p < 0.001), attack duration (β = -0.159,
p = 0.001), and headache chronicity (β = -0.130, p = 0.012). Headache chronicity had a direct effect on the MSQoL
score and exerted an indirect effect on the MSQoL score through the MIDAS and the BDI scores.
Conclusions: Chronic migraine appears to impair QOL directly as well as indirectly by provoking disability and
depression.
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 Patients with chronic migraine were more likely to
have a lower education level, higher attack
frequency, higher pain intensity, and higher
frequency of cephalic allodynia, than those with
episodic migraine.
 QOL in patients with chronic migraine is also
significantly lower, because of both the direct effects
of chronicity, and the indirect (increasing the
frequency of disability and depression) effects.* Correspondence: sppark@mail.knu.ac.kr
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In the newly released version of the Global Burden of
Disease study of 2010, migraine is responsible for almost
3% of disability attributable to a specific disease world-
wide. After including its comorbidities, migraine should
be considered among the most disabling of diseases [1].
Indeed, it is considered the most disabling among neuro-
logical disorders, and the eighth most burdensome dis-
ease [1,2]. Migraine is a common neurological disorder,
with 1-year prevalence ranging from 4.5% to 8% for
men, and from 8% to 16% for women [3-5]. In a
population-based survey from Korea, the prevalence of
migraine is somewhat lower, at 2.9% for men and 9.2%
for women [6]. Migraine can be considered a chronic
disorder, with episodic attacks and potential progression
to more frequent and severe attack patterns [7]. With re-
gard to headache chronicity, migraine is classified intoan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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is defined by the International Classification of Head-
ache Disorders, second edition (ICHD-2), as a headache
frequency of ≥15 days per month on average over the
preceding 3 months [8]. Although the prevalence of CM
in the general population is as low as 1.4%–2.2% [9], the
disease burden of CM was highlighted in several studies
[10-13]. In the American Migraine Prevalence and Pre-
vention (AMPP) study, patients with CM had 2 times
higher developing depression, anxiety, and chronic pain
than those with EM [14]. In addition, health care costs
and productivity loss at work were larger in patients
with CM than those with EM [10,11]. The International
Burden of Migraine Study (IBMS) collected data from
several countries in Western Europe, North America
and the Asia/Pacific regions, and reported that patients
with CM demonstrated greater disability, a lower quality
of life (QOL), and higher levels of anxiety and depres-
sion, than those with EM [12,13]. CM and depression
are in fact known risk factors for suicide behavior or
ideation in patients with migraine [15,16].
Reduced QOL was reported in patients with migraine
when compared with age- and sex-matched people with-
out migraine [17-19]. Patients with migraine demon-
strated significant impairment of QOL compared to the
controls, independent of depression or anxiety [20,21].
Although several predictors for QOL in patients with
migraine were proposed, depression and migraine-
associated factors were the most consistent ones
[12,14,17,20,22-24]. Migraine disability [20,22,24], head-
ache intensity [22-24], CM [12,14,19], and attack fre-
quency [20,23,24] were involved in migraine-associated
factors. A community-based study for women with mi-
graine analyzed the interrelationship of headache intensity,
chronic pain experience, and depression with disability or
QOL, using the regression model [23]. However, it in-
cluded only women as a study population and did not
consider CM as a risk factor. The purposes of the study
are 1) to examine clinical, psychiatric, and QOL of CM
compared to EM; and 2) to evaluate how headache chron-




We included patients with migraine who attended the out-
patient clinic in Department of Neurology at Kyungpook
National University Hospital from November 9, 2010 to
August 31, 2012. A diagnosis of migraine was assigned
based on the International Classification of Headache
Disorders, second edition (ICHD-2) [8]. Headache chron-
icity was defined as whether patients had EM or CM. The
definition of CM was determined by the criteria of ICHD-
2 Revised, which considered CM as ≥15 headache daysper month on average over the preceding 3 months, and
with at least 8 days/month either meeting criteria for mi-
graine without aura or responding to migraine-specific
medication [25]. This study included patients who were
between 15 and 70 years of age and who agreed to partici-
pate in the study. Patients who took migraine-specific
medications (triptans, ergot, or preventive medicines) or
psychotropic agents (antidepressants, anxiolytics, or anti-
psychotics) at any time in the preceding year were ex-
cluded. Patients with severe medical, psychiatric, or
neurological disorders, mental retardation, and alcohol or
drug abuse that prevented them from understanding the
questionnaires and cooperating with the study were also
excluded.
Study design
This is a cross-sectional study and each patient was en-
rolled consecutively. Each patient was interviewed by a
trained neurologist (SPP) who also reviewed the patient’s
medical charts to collect demographic and clinical infor-
mation for a computerized database. Sociodemographic
data were collected on variables including age, gender,
education, job (having a job or not), income (earning at
least 1 million KRW per month, equivalent to 980 USD
per month or not), marital status (married or single, di-
vorced, and bereaved), and concurrent medical diseases
(suffering from medical diseases or not). Clinical data in-
cluded age at onset, disease duration, attack frequency
and duration, headache intensity, accompanying symp-
toms (e.g., photophobia, phonophobia, and cephalic allo-
dynia) and family history. Attack frequency meant the
number of migraine attacks for preceding 3 months.
Headache intensity was measured by the Visual Analog
Scale (VAS). The VAS was measured in two different
ways—the VASmax and VASnow. VASmax meant the max-
imal intensity of headaches experienced during the prior
3 months, and VASnow represented the intensity of head-
ache on the day of answering the self-report question-
naires. Cephalic allodynia was assessed by a simple
questionnaire with dichotomous options (yes or no). Pa-
tients were asked to recall whether they had abnormal
skin sensitivity on their face or scalp especially when
they engaged in any of the following activities during mi-
graine attack: (1) combing hair; (2) pulling hair back; (3)
shaving face; (4) wearing eyeglasses; (5) wearing earrings;
(6) taking a shower (when shower water hits the face);
(7) being exposed to cold. If patients experienced any of
these, we considered them positive for allodynia. Family
history of migraine was defined as the existence of mi-
graine in a lineal ascendant and siblings. All subjects
completed reliable and validated self-report question-
naires, including the Korean versions of the Migraine
Disability Assessment Scale (MIDAS) [26], the Beck De-
pression Inventory (BDI) [27], the Beck Anxiety Inventory
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(MSQoL) [29]. We compared clinical, psychiatric, and
QOL of CM with those of EM, and evaluated the role of
CM on QOL with respect to other variables.
Questionnaires
Migraine Disability Assessment Scale (MIDAS)
The Korean version of the MIDAS, a five-item question-
naire designed to evaluate disability within the most re-
cent 3 months, was used in this study [26]. Patients were
asked to report decreased performance in the domains
of work/school, household work, and family/social activ-
ities. Scores (0–27), measured the overall level of disabil-
ity: Grade I (0–5), Grade II (6–10), Grade III (11–20),
and Grade IV (above 21). Cronbach’s α value was 0.75.
Beck Depression Inventory (BDI)
The BDI is the most commonly used self-rating scale for
depression [27]. Participants rated 21 items on a scale
from 0 to 3 according to how they felt at the time. Sub-
jects who scored above 16 were considered to have de-
pression. Cronbach’s α value was 0.8.
Beck Anxiety Inventory (BAI)
The BAI is a 21-item self-report measure of anxiety se-
verity, with each item describing a common symptom of
anxiety [28]. The respondent is asked to rate how much
he or she has been bothered by anxiety symptoms dur-
ing the previous week on a 4-point scale (0–3). Subjects
who score above 21 are considered to suffer from anx-
iety. Cronbach’s α values was 0.9.
Migraine-Specific Quality of Life (MSQoL)
The MSQoL was developed by Wagner et al., and has
proven to be a valid and reliable tool in clinical migraine
research [30]. It is a 25-item questionnaire translated
into and validated for the Korean language [29]. The
items are rated on a 4-point scale (1–4). A lower total
score (overall range of 25–100) indicates poorer QOL.
Cronbach’s α value was 0.93.
Statistical analysis
Data for continuous variables were expressed as means ±
SD, and those for categorized variables were expressed
as frequencies. The independent t test, Mann-Whitney
U test, and Fisher’s exact test were applied to compare
variables between EM and CM. Not only demographic, so-
cioeconomic, and clinical variables, but also questionnaire
scores were included as independent variables to measure
predictors of the MSQoL score, by multiple linear regres-
sion analyses with stepwise selection. The probabilities of
entry and exit were 0.05 and 0.1, respectively. Collinearity
was addressed by performing the appropriate statistics.
Variables selected from the linear regression analyses wereused to construct a structural equation model to test the in-
terrelations between variables and the MSQoL score. Based
on a review of previous studies [12,14,17,19,20,22-24], we
developed a hypothetical model outlining the path of de-
pression, migraine disability, gender, attack duration, head-
ache chronicity (indicating CM), and gender to QOL. We
hypothesized that all of these variables influenced on QOL
directly, and gender, headache chronicity, and attack dur-
ation influenced on QOL indirectly through the mediation
of migraine disability and depression. The hypothesized
path model was tested with structural equation model.
Model fit was evaluated using path analysis, a method that
allows for estimation of the relative importance of different
paths of the independent variables onto the dependent vari-
ables. An acceptable model fit was defined as having a non-
significant chi-square (χ2) value, a Normed Fit Index (NFI)
of ≥0.9, a Comparative Fit Index (CFI) of ≥0.9, a Goodness
of Fit Index (GFI) of ≥0.9, and a Root Mean-square Re-
sidual (RMR) of ≤0.05. Structural equation modeling was
used to estimate the total effect of each predictor, in order
to establish a linear model to predict the MSQoL score
with these interrelations accounted for. Except for the
structural equation model, all statistical analyses were con-
ducted with SPSS Version 20 (IBM SPSS Inc). LISREL 8.8
for Windows (Scientific Software International, USA) was
used for the path and structural equation modeling compo-
nents of the analysis. The level of statistical significance was
set at 0.05.
Ethics or Institutional review board approval
This cross-sectional study was approved by the Institu-
tional Review Board of Kyungpook National University
Hospital, and all participants provided written informed
consent prior to their participation.
Results
A total of 307 patients with migraine consecutively vis-
ited our clinic during the study period. Among them, 56
patients were excluded because of refusal to complete
the questionnaires (n = 28); probable migraine (n = 12);
mental retardation (n = 3); illiteracy (n = 5); or age older
than 70 (n = 8). Subsequently, 251 patients (212 men/39
women, mean age 38.9 ± 12.9 years old) completed the
study. With respect to headache chronicity, 183 patients
(72.9%) had EM and 68 patients (27.1%) had CM. Demo-
graphic and clinical characteristics between EM and CM
are documented in Table 1. Patients with CM had a
lower level of education (p = 0.002), higher attack fre-
quency (p < 0.001), higher VASnow score (p < 0.001), and
higher frequency of cephalic allodynia (p = 0.03), than
those with EM. Concurrent medical disease were denoted
in 58 patients with migraine; endocrinologic (n = 13), car-
diovascular (n = 12), gastrointestinal (n = 9), neurological
(n = 7), orthopedical (n = 7), otolaryngeal (n = 7), pulmonary
Table 1 Demographic and clinical characteristics with respect to headache chronicity
Mean ± SD (range) or number (%)
p value*
Episodic migraine Chronic migraine
(n = 183) (n = 68)
Age, year 38.0 ± 12.7 (15-65) 41.4 ± 13.4 (15-70) 0.063
Gender, female 152 (83.1) 60 (88.2) 0.433
Education, year 13.0 ± 3.2 (6-18) 11.5 ± 3.5 (4-18) 0.002
Job, yes 81 (44.3) 27 (39.7) 0.568
Income, at least 1 million KRW/month 73 (39.9) 24 (35.3) 0.561
Marriage, married but not divorced or bereaved 114 (62.3) 50 (73.5) 0.103
Concurrent medical disease, yes 43 (23.5) 15 (22.1) 0.868
Age at onset, year 27.5 ± 11.4 (7-55) 29.0 ± 12.7 (6-63) 0.341
Disease duration, year 10.5 ± 8.9 (1-40) 12.4 ± 9.3 (1-40) 0.138
Attack frequency, /3 months 7.2 ± 8.3 (1-50) 28.2 ± 26.6 (5-90) <0.001
Attack duration, hour 26.4 ± 25.9 (2-72) 32.7 ± 32.9 (3-120) 0.112
VASmax
† 7.6 ± 2.3 (0-10) 8.2 ± 1.7 (3-10) 0.106
VASnow
‡ 2.1 ± 2.2 (0-10) 3.9 ± 2.7 (0-10) <0.001
Photophobia 78 (42.6) 37 (54.4) 0.117
Phonophobia 104 (56.8) 47 (69.1) 0.083
Cephalic allodynia 22 (12.0) 16 (23.5) 0.03
Family history 105 (57.4) 38 (55.9) 0.886
*Independent t test, Mann-Whitney U test, or Fisher’s exact test was applied.
†Maximal headache intensity during the preceding 3 months.
‡Headache intensity on the day conducting the questionnaires.
KRW: Korean Won, VAS: Visual Analog Scale.
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dermatologic diseases (n = 1). Its frequency between EM
and CM was not different.
Migraine disability, psychiatric symptoms, and QOL
comparisons between EM and CM are listed in Table 2.
Patients with CM showed a higher mean MIDAS score
than those with EM (p < 0.001), and the proportion of
patients with migraine with MIDAS score ≥ 21 (grade IV
severe disability) was also higher for CM, at 70.6% versus
37.2% for EM (p < 0.001). Patients with CM had a higher




MIDAS score 26.5 ± 32.6 (0-180)
MIDAS, grade III and IV 114 (62.3)
BDI score 13.4 ± 9.7 (0-42)
Depression, >16 on BDI 55 (30.1)
BAI score 12.6 ± 10.0 (0-47)
Anxiety, >21 on BAI 32 (17.5)
MSQoL score 67.3 ± 15.0 (29-96)
*Independent t test, Mann-Whitney U test, or Fisher’s exact test was applied.
MIDAS: Migraine Disability Assessment Scale, BDI: Beck Depression Inventory, BAI: Bas a higher frequency of depression (p = 0.001). The re-
sults of the mean BAI score and the frequency of anxiety
were comparable to those of the mean BDI score and
the frequency of depression. Finally, the mean MSQoL
score was lower in patients with CM than those with
EM (p < 0.001).
Predictors of the MSQoL score determined by step-
wise linear regression analyses are depicted in Table 3.
The strongest predictor was the BDI score (β = -0.373,
p < 0.001), followed by the MIDAS score (β = -0.223,
p < 0.001), gender (β = -0.192, p < 0.001), attack durationand quality of life with respect to headache chronicity




54.1 ± 49.9 (0-180) <0.001
55 (80.9) 0.006
18.7 ± 10.5 (0-46) <0.001
36 (52.9) 0.001
18.9 ± 12.6 (1-61) <0.001
26 (38.2) 0.001
56.0 ± 16.5 (25-94) <0.001
eck Anxiety Inventory, MSQoL: Migraine-Specific Quality of Life.
Table 3 Predictors determining the MSQoL score by







BDI score −0.373 <0.001 1.206
MIDAS score −0.223 <0.001 1.238
Gender −0.192 <0.001 1.047




MSQoL: Migraine-Specific Quality of Life, BDI: Beck Depression Inventory,
MIDAS: Migraine Disability Assessment Scale.
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p = 0.012). In other words, high depression symptoms,
high migraine disability, female gender, a long duration of
headache, and CM all contributed to decreasing QOL.
Stepwise regression produced a five-variable model that
explained 42.7% of the variance in the MSQoL score. Ac-
cording to the standardized β, the contribution of BDI
score to QOL was 1.67 times higher than that of the
MIDAS score, 1.94 times higher than that of gender, 2.35
times higher than that of attack duration, and 2.87 times
higher than that of headache chronicity. Colinearity statis-
tics indicated that these variables had independent effects
without redundancy.
Complex interrelationships between predictors and the
MSQoL score were illustrated by the refined path ana-
lysis model in Figure 1. According to pre-defined cri-
teria, the final model provided an excellent fit to the
data (χ2 = 3.12, p = 0.37; NFI = 0.99; CFI = 1; GFI = 1; RMR
= 0.025). All regression coefficients were statisticallyFigure 1 Interrelationships between clinical variables and
Migraine-Specific Quality of Life (MSQoL) score by refined path
analysis model. An arrow indicates a direct relationship from
variable to another. Numbers denote standardized regression coefficients
(beta weights) for each path. If the sign of the coefficient is negative,
when the predictor variable score increases by 1 standard deviation,
MSQoL score decreases by the number of standard deviations as
indicated by the value of the coefficient. All regression coefficients are
statistically significant (p<0.01). MIDAS: Migraine Disability Assessment
Scale, BDI: Beck Depression Inventory, MSQoL: Migraine-Specific Quality
of Life.significant (p < 0.01). Gender, headache chronicity, attack
duration, the MIDAS score, and the BDI score exerted dir-
ect effects on the MSQoL score. Female gender exerted an
indirect effect on the MSQoL via the BDI score. Headache
chronicity revealed an indirect effect on the MSQoL score
through the MIDAS and the BDI scores. The MIDAS score
exerted an indirect effect on the MSQoL through the BDI
score. Unlikely to the hypothesized path model, gender did
not have an indirect effect on the MIDAS score and attack
duration did not exert an indirect effect on the MIDAS and
BDI scores.Discussion
We determined that almost one-fourth of eligible pa-
tients had CM. Patients with CM were more likely to
have a low education level, a high attack frequency, a
large pain intensity, and a high frequency of cephalic
allodynia than those with EM. Furthermore, they ap-
peared to have greater migraine disability, higher depres-
sion and anxiety symptoms, and poorer QOL than those
with EM. Among these variables, depression symptoms,
migraine-associated disability, being female, long dur-
ation of headaches, and headache chronicity mainly con-
tributed to the decreased QOL. Headache chronicity had
a direct effect on QOL and indirect effects on QOL, in-
ducing migraine disability and depression.
The prevalence of CM with respect to the study design
is different. Only about 5–6% of respondents were diag-
nosed with CM in the larger population-based studies
[12,14], whereas more than half of patients with mi-
graine demonstrated CM in several hospital-based stud-
ies [31,32]. The frequency of CM in our patients was
within the range of the hospital-based studies. The fea-
tures of clinical and demographic characteristics of pa-
tients with CM in this study were similar to those of
patients in other studies [13,14,33,34]. In general, the
frequency of cutaneous allodynia in patients with mi-
graine is about 60–70%, and does not differ between
CM and EM [34]. Contrary to this finding, in our study
the frequency of cephalic allodynia was somewhat lower,
by as much as 22% in patients with CM and 16% in
those with EM, and patients with CM demonstrated a
significantly higher frequency of it than those with EM.
The low frequency of allodynia in our study may be ex-
plained by three ways. First, we measured only cephalic
allodynia, ignoring extracephalic allodynia originated
from body or extremities. Second, we did not examine
allodynia, by using a specific tool such as quantitative
sensory testing or dynamic mechanical method including
brushing. Third, the low frequency of allodynia may be
related to the ethnic difference. A further study to com-
pare the prevalence of allodynia in one race versus an-
other should be done.
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ability, emotional burden and QOL in two large observa-
tional studies (the AMPP and IBMS studies) and one
hospital-based Taiwanese study [11-14,32]. The AMPP
study is a large, United States (US) population-based
longitudinal survey that identified 24,000 respondents
with headache and followed them annually for 5 years
[11,14]. The IBMS is a web-based, cross-sectional, multi-
national survey that identified and evaluated persons
with CM or EM [12,13]. The Taiwanese study is a well-
designed, clinic-based study, which recruited as many
patients with CM as with EM (CM, n = 167 (50.5%) vs.
EM, n = 164 (49.5%)) [32]. In the IBMS study, the fre-
quency of MIDAS grade IV scores was 78% for CM and
23.3% for EM [12], and in the Taiwanese study, 59.3%
for CM and 21.9% for EM [32]. Our study also demon-
strated a greater headache-related disability in patients
with CM than those with EM. The frequency of MIDAS
grade IV scores was 70.6% in patients with CM, which
was almost double that of patients with EM (35.2%). We
further found that the frequency of depression in pa-
tients with CM was 52.9%, which was higher than that
of those with EM (30.1%). The frequency of anxiety was
also higher in patients with CM (38.2%) than with EM
(17.5%). Consistent with our study, the levels of anxiety
and depression were higher in patients with CM in both
population-based and hospital-based studies. The AMPP
study found that patients with CM were twice as likely
to have depression and anxiety compared with those
with EM [14]. The IBMS study and the Taiwanese study
also reported that moderate to severe anxiety and de-
pression were specifically more prominent for CM com-
pared to EM (47.0% vs. 25.1% in IBMS, 33.5% vs. 7.9% in
the Taiwanese study) [13,32].
One benefit of our study is clarification of the interre-
lationships among the variables that influence QOL. We
found that headache chronicity had both direct and in-
direct effects on QOL by inducing migraine disability
and depression. Headache chronicity has a weak direct
relationship to MSQoL when compared with its indirect
relationships. We suggest that the impact of headache
chronicity on QOL might be stronger when it induces
disability and depression. An interesting point in our
study was that female gender was one of the contribut-
ing factors in determining QOL directly, as well as indir-
ectly by provoking depression. Several representative
population-based studies examining the disease burden
of migraine did not identify female gender as a risk fac-
tor for QOL [19,20,24]. Only one clinic-based study sug-
gested female gender was a significant predictor of
impaired QOL [22]. The pathophysiological mechanism
between female gender and QOL in migraine is not
clear, but certain reproduction-related hormonal changes
might place women at increased risk for depression,migraine and increased chronicity of headache [35,36].
These notable gender differences could bring about im-
paired QOL, but to confirm this link, further study
about gender-specific influences of migraine on QOL
would be required.
Conclusion
In this study, we demonstrated that headache chronicity
and its impact on headache disability also elicited de-
pression. Therefore, early identification and appropriate
management of CM might lessen headache disability
and depression both, and thereby improve QOL. Recent
trials of topiramate and botulinum toxin type A were
also encouraging, demonstrating that the drugs im-
proved QOL in patients with CM [37]. Another way to
improve QOL would be to screen for depression symp-
toms when the patients visit a headache clinic. Brief,
self-reported questionnaires such as the Hospital Anx-
iety and Depression Scale (HADS) or the 9-item Patient
Health Questionnaire (PHQ-9) may be enough to detect
symptoms early [38]. Although no studies have proven
that the treatment of depression in patients with CM
would improve their QOL, our study can act as a spring-
board towards future investigation of that issue.
Some limitations should be considered when interpret-
ing the results of this study. First, this is a hospital-based
study, so seriously ill individuals were more likely to be
recruited, and thus their comorbidities might be overes-
timated. Therefore, a population-based study to measure
QOL is needed. Second, we used only self-administered
psychometric instruments to test our eligible patients.
This protocol did not include structured interviews, such
as the Structured Clinical Interview for DSM-IV axis I
disorders (SCID) [39], which are considered the gold
standard for research regarding psychiatric problems.
However, the BDI and BAI are good screening tools for
depression and anxiety for physicians other than psychi-
atrists, and are both well-validated tests frequently used
for screening and for grading in headache studies [40].
Third, we did not use the MSQ 2.1, which is the more
popular way to measure QOL in patients with EM and
CM [41]. The MSQ 2.1 is the most frequently utilized
tool assessing migraine-specific QOL, but its reliability
and validity have not yet been measured in Korean pa-
tients with migraine. Future studies to identify predictors
of QOL using the MSQ 2.1 in a Korean population will
need to be done.
In summary, patients with CM had more serious clin-
ical, psychiatric, and poor QOL than did patients with
EM. CM appears to impair QOL directly as well as in-
directly by provoking disability and depression.Competing interests
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